NFE2L2 and bronchopulmonary dysplasia: Qian et al. showed that administering a single injection of Aurothioglucose (ATG, an FDA-approved thioredoxin reductase inhibitor) to BPD mice to activate Nrf2 activity could inhibit the progression of BPD to some extent [10].